J&J uncorks long-term data for Crohn’s disease candidate; Age-related disease biotech earns Eli Lilly’s backing

J&J and AbbVie are competing for the same Crohn’s disease market with their respective IL-23 drugs, Tremfya and Skyrizi. On Wednesday, J&J’s Janssen unit revealed data it thinks could prove a key differentiator but appears to lack key context.

In long-term, Phase II follow-up data stretching...

Click to view original post